Hancock Whitney Corp Has $3.04 Million Stock Holdings in Bristol-Myers Squibb Co (NYSE:BMY)

Hancock Whitney Corp grew its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 15.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 47,422 shares of the biopharmaceutical company’s stock after buying an additional 6,308 shares during the quarter. Hancock Whitney Corp’s holdings in Bristol-Myers Squibb were worth $3,044,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in BMY. Wealthcare Capital Management LLC increased its position in Bristol-Myers Squibb by 47.7% in the fourth quarter. Wealthcare Capital Management LLC now owns 517 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 167 shares during the period. Psagot Investment House Ltd. boosted its holdings in Bristol-Myers Squibb by 4.6% during the third quarter. Psagot Investment House Ltd. now owns 4,038 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 178 shares during the last quarter. Jupiter Wealth Management LLC boosted its holdings in Bristol-Myers Squibb by 2.3% during the fourth quarter. Jupiter Wealth Management LLC now owns 8,180 shares of the biopharmaceutical company’s stock worth $543,000 after buying an additional 180 shares during the last quarter. Elmwood Wealth Management Inc. boosted its holdings in Bristol-Myers Squibb by 1.6% during the fourth quarter. Elmwood Wealth Management Inc. now owns 11,229 shares of the biopharmaceutical company’s stock worth $721,000 after buying an additional 180 shares during the last quarter. Finally, Corundum Group Inc. boosted its holdings in Bristol-Myers Squibb by 3.6% during the fourth quarter. Corundum Group Inc. now owns 5,341 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 184 shares during the last quarter. Institutional investors own 84.33% of the company’s stock.

NYSE:BMY opened at $66.08 on Friday. Bristol-Myers Squibb Co has a fifty-two week low of $42.48 and a fifty-two week high of $68.34. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.83 and a quick ratio of 3.72. The stock has a market capitalization of $109.02 billion, a PE ratio of 30.17, a price-to-earnings-growth ratio of 1.29 and a beta of 0.76. The business’s 50-day simple moving average is $64.96 and its 200-day simple moving average is $55.92.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.22 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.34. Bristol-Myers Squibb had a return on equity of 48.97% and a net margin of 13.15%. The business had revenue of $7.95 billion for the quarter, compared to analysts’ expectations of $6.20 billion. During the same quarter in the previous year, the business posted $0.94 EPS. Bristol-Myers Squibb’s revenue for the quarter was up 33.0% on a year-over-year basis. On average, research analysts expect that Bristol-Myers Squibb Co will post 6.16 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were issued a dividend of $0.45 per share. This represents a $1.80 annualized dividend and a dividend yield of 2.72%. The ex-dividend date of this dividend was Thursday, January 2nd. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. Bristol-Myers Squibb’s payout ratio is 38.38%.

A number of brokerages have issued reports on BMY. UBS Group raised their target price on Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a report on Wednesday, October 23rd. Wolfe Research set a $66.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Friday, November 1st. Argus upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a report on Friday, December 13th. Mizuho began coverage on Bristol-Myers Squibb in a report on Monday, November 25th. They set a “buy” rating on the stock. Finally, Morgan Stanley began coverage on Bristol-Myers Squibb in a report on Friday, November 22nd. They set an “equal weight” rating and a $60.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have assigned a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Buy” and an average price target of $61.69.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: How can investors find ex-dividend dates?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.